Keli Walbert - 08 Jan 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for Keli Walbert
Issuer symbol
APLS
Transactions as of
08 Jan 2025
Net transactions value
+$507,804
Form type
4
Filing time
10 Jan 2025, 17:39:26 UTC
Next filing
15 Dec 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Award $0 +9,090 $0.000000 9,090 08 Jan 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Award $507,804 +15,388 $33.00 15,388 08 Jan 2025 Common Stock 15,388 $33.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This restricted stock unit was granted on January 8, 2025. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to her continued service as a director, or upon later termination of her service as a director at her election.
F2 This represents a stock option award granted January 8, 2025 that vest 1/3rd per year over a three-year period subject to continued service.